Revance Therapeutics (NASDAQ:RVNC) has been given a $50.00 price target by Cantor Fitzgerald in a report issued on Tuesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 92.31% from the company’s previous close.

RVNC has been the subject of a number of other reports. Zacks Investment Research raised Revance Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 target price for the company in a research note on Wednesday, August 30th. Piper Jaffray Companies reissued a “buy” rating and set a $28.00 target price on shares of Revance Therapeutics in a research note on Friday, October 27th. Finally, Barclays initiated coverage on Revance Therapeutics in a research note on Monday, November 27th. They set an “overweight” rating and a $31.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. Revance Therapeutics has an average rating of “Buy” and an average price target of $34.86.

Revance Therapeutics (RVNC) traded down $1.65 during trading on Tuesday, reaching $26.00. 257,300 shares of the company’s stock were exchanged, compared to its average volume of 184,325. Revance Therapeutics has a 52 week low of $15.85 and a 52 week high of $28.75.

Revance Therapeutics (NASDAQ:RVNC) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.06). The business had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.05 million. Revance Therapeutics had a negative net margin of 37,161.00% and a negative return on equity of 67.85%. The business’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.64) earnings per share. equities research analysts anticipate that Revance Therapeutics will post -3.73 earnings per share for the current year.

In other Revance Therapeutics news, CEO L Daniel Browne sold 7,600 shares of the firm’s stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of $23.58, for a total transaction of $179,208.00. Following the completion of the sale, the chief executive officer now owns 148,450 shares of the company’s stock, valued at approximately $3,500,451. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mark J. Foley purchased 20,000 shares of the business’s stock in a transaction on Tuesday, November 7th. The shares were acquired at an average cost of $26.96 per share, with a total value of $539,200.00. Following the acquisition, the director now directly owns 6,000 shares in the company, valued at $161,760. The disclosure for this purchase can be found here. In the last three months, insiders sold 44,026 shares of company stock valued at $1,135,234. 18.86% of the stock is currently owned by insiders.

A number of institutional investors have recently made changes to their positions in the business. Pura Vida Investments LLC acquired a new stake in Revance Therapeutics during the 3rd quarter valued at $1,378,000. Schwab Charles Investment Management Inc. increased its position in Revance Therapeutics by 4.9% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 117,258 shares of the biopharmaceutical company’s stock worth $3,231,000 after buying an additional 5,501 shares during the period. EAM Investors LLC increased its position in Revance Therapeutics by 113.9% during the 3rd quarter. EAM Investors LLC now owns 72,518 shares of the biopharmaceutical company’s stock worth $1,998,000 after buying an additional 38,621 shares during the period. SG Americas Securities LLC bought a new position in Revance Therapeutics during the 3rd quarter worth $144,000. Finally, Alps Advisors Inc. increased its position in Revance Therapeutics by 11.1% during the 3rd quarter. Alps Advisors Inc. now owns 30,351 shares of the biopharmaceutical company’s stock worth $836,000 after buying an additional 3,027 shares during the period. 88.70% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This piece was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/05/revance-therapeutics-rvnc-given-a-50-00-price-target-at-cantor-fitzgerald-2.html.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.